Myriocin, a competitive inhibitor of serine palmitoyltransferase 1 (SPTLC1), the first enzyme in de novo sphingolipid biosynthesis, can inhibit the proliferation of different cancer types by altering the sphingolipid rheostat (Lee et al., 2012; Yaguchi et al., 2017). Here, SPTLC1 is linked to cancer.